Oscar Health posts strong Q1 2026 with $4.65B revenue and 52.7% growth, raising price target to $30.

Oscar Health reported impressive Q1 2026 results with $4.65 billion in revenue, marking a 52.7% year-over-year increase and a 70.5% medical loss ratio. The company demonstrated strong operating efficiency driven by its technology platform and SG&A leverage, achieving an adjusted EBITDA of $727.1 million and a low SG&A ratio. The analyst reaffirmed a Strong Buy rating and raised the 2026 price target to $30, citing robust execution and confidence in management despite sector risks like policy uncertainty. This performance supports a bullish outlook for Oscar Health's future growth and market position.